HomeCompareALBO vs ADC

ALBO vs ADC: Dividend Comparison 2026

ALBO yields 4.53% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $152.0K in total portfolio value· pulled ahead in Year 3
10 years
ALBO
ALBO
● Live price
4.53%
Share price
$44.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.9K
Annual income
$605.56
Full ALBO calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — ALBO vs ADC

📍 ADC pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALBOADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALBO + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALBO pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALBO
Annual income on $10K today (after 15% tax)
$385.05/yr
After 10yr DRIP, annual income (after tax)
$514.73/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $68,162.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALBO + ADC for your $10,000?

ALBO: 50%ADC: 50%
100% ADC50/50100% ALBO
Portfolio after 10yr
$102.9K
Annual income
$40,701.43/yr
Blended yield
39.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

ALBO
Analyst Ratings
7
Buy
5
Hold
Consensus: Buy
Price Target
$44.00
-0.3% upside vs current
Range: $42.00 — $48.00
Altman Z
0.5
Piotroski
4/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALBO buys
0
ADC buys
0
No recent congressional trades found for ALBO or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALBOADC
Forward yield4.53%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$26.9K$178.9K
Annual income after 10y$605.56$80,797.29
Total dividends collected$5.3K$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$44.00$81.06

Year-by-year: ALBO vs ADC ($10,000, DRIP)

YearALBO PortfolioALBO Income/yrADC PortfolioADC Income/yrGap
1$11,153$453.00$10,990$580.36+$163.00ALBO
2$12,406$472.18$12,301$860.26+$105.00ALBO
3← crossover$13,765$490.86$14,104$1,298.62$339.00ADC
4$15,238$509.01$16,691$2,008.16$1.5KADC
5$16,831$526.60$20,580$3,205.09$3.7KADC
6$18,553$543.61$26,754$5,330.02$8.2KADC
7$20,411$560.02$37,196$9,345.14$16.8KADC
8$22,416$575.82$56,244$17,523.09$33.8KADC
9$24,576$591.00$94,286$35,736.21$69.7KADC
10$26,902$605.56$178,949$80,797.29$152.0KADC

ALBO vs ADC: Complete Analysis 2026

ALBOStock

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Full ALBO Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this ALBO vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALBO vs SCHDALBO vs JEPIALBO vs OALBO vs KOALBO vs MAINALBO vs NNNALBO vs EPRTALBO vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.